HIV-HCV共感染者SVR前后肝纤维化无创标志物变化
该研究基于加拿大共感染队列,比较HIV-HCV共感染者获得持续病毒学应答(SVR)前后APRI与瞬时弹性成像(TE)的变化。结果显示TE在SVR后显著下降,而APRI变化有限,提示TE应作为监测纤维化消退的首选无创工具。
要点
- HIV-HCV共感染者获得SVR后,TE值显著下降,APRI变化有限。
- TE应作为监测纤维化消退的首选无创工具。
- 未来需根据TE轨迹评估肝细胞癌等肝脏结局风险。
核心结论
- 在HIV-HCV共感染者中,获得SVR后TE值显著下降,而APRI变化有限,TE应作为监测纤维化消退的首选无创工具。
研究设计与样本
- 加拿大共感染队列研究,纳入首次接受干扰素/利巴韦林或直接抗病毒药物(DAA)治疗获得SVR且至少有一次治疗前后纤维化测量的患者。
- 1981例患者中,151例经干扰素获得SVR,553例经DAA获得SVR;分别有94例和382例符合纳入标准。
- 使用广义加性混合模型(假设伽马分布)对APRI或TE(仅DAA时代)的变化建模,调整性别、HCV感染年龄、HCV感染持续时间及时间依赖的BMI、暴饮和可检测HIV RNA。
临床怎么用
- 对于HIV-HCV共感染者获得SVR后,优先使用TE而非APRI监测肝纤维化消退。
局限性
- 研究仅纳入有治疗前后纤维化测量数据的患者,TE分析仅限DAA时代。
- 未来需根据TE测量的纤维化消退轨迹评估肝细胞癌等肝脏结局风险,以确定是否及何时可安全停止筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noninvasive markers of liver fibrosis such as aspartate aminotransferase-to-platelet ratio (APRI) and transient elastography (TE) have largely replaced liver biopsy for staging hepatitis C virus (HCV). As there is little longitudinal data, we compared changes in these markers before and after sustained virologic response (SVR) in human immunodeficiency virus (HIV)-HCV coinfected patients. METHODS: Participants from the Canadian Coinfection Cohort study who achieved SVR after a first treatment with either interferon/ribavirin or direct acting antivirals (DAAs), with at least 1 pre- and posttreatment fibrosis measure were selected. Changes in APRI or TE (DAA era only) were modeled using a generalized additive mixed model, assuming a gamma distribution and adjusting for sex, age at HCV acquisition, duration of HCV infection, and time-dependent body mass index, binge drinking, and detectable HIV RNA. RESULTS: Of 1981 patients, 151 achieved SVR with interferon and 553 with DAAs; 94 and 382 met inclusion criteria, respectively. In the DAA era, APRI increased (0.03 units/year; 95% credible interval (CrI): -.05, .12) before, declined dramatically during, and then changed minimally (-0.03 units/year; 95% CrI: -.06, .01) after treatment. TE values, however, increased (0.74 kPa/year; 95% CrI: .36, 1.14) before treatment, changed little by the end of treatment, and then declined (-0.55 kPa/year; 95% CrI: -.80, -.31) after SVR. CONCLUSIONS: TE should be the preferred noninvasive tool for monitoring fibrosis regression following cure. Future studies should assess the risk of liver-related outcomes such as hepatocellular carcinoma according to trajectories of fibrosis regression measured using TE to determine if and when it will become safe to discontinue screening.
引用
- Kronfli N, Young J, Wang S, et al. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis. 2021. PMID: 32504083. doi:10.1093/cid/ciaa702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。